showed that dupilumab induces a profound decrease in sIgE levels of several food allergens in adult AD patients with comorbid FA, highlighting the positive effect of blocking IL‐4 and IL‐13 signaling on sIgE levels.5 This evidence concerns the gene IL13 and Alzheimer disease.